Key result
Ginsenoside Rg1 significantly improved bone mass and microstructural deterioration in diabetic rats by promoting type H angiogenesis and osteogenic coupling via the VEGF/Notch/Noggin pathway.
Why the study?
Ginsenoside Rg1 has demonstrated antidiabetic and antiosteoporotic activities, but its protective effect against diabetic osteoporosis and the underlying mechanism required investigation.
p-value: p=<0.05
Ginsenoside Rg1 shows potential as a treatment for diabetic osteoporosis by promoting type H angiogenesis and osteogenic coupling in preclinical models.
Supports hypothesis that Rg1 may benefit diabetic osteoporosis; leaves open translation to humans pending clinical trials.
Ginsenoside Rg1 (Rg1) has been demonstrated to have antidiabetic and antiosteoporotic activities. The aim of this study was to investigate the protective effect of Rg1 against diabetic osteoporosis and the underlying mechanism. In vitro , we found that Rg1 increased the number of osteoprogenitors and alleviated high glucose (HG) induced apoptosis of osteoprogenitors by MTT assays and flow cytometry. qRT‒PCR and western blot analysis suggested that Rg1 can also promote the secretion of vascular endothelial growth factor (VEGF) by osteoprogenitors and promote the coupling of osteogenesis and angiogenesis. Rg1 can also promote the proliferation of human umbilical vein endothelial cells (HUVECs) cultured in high glucose, enhance the angiogenic ability of endothelial cells, and activate the Notch pathway to promote endothelial cells to secrete the osteogenesis-related factor Noggin to regulate osteogenesis, providing further feedback coupling of angiogenesis and osteogenesis. Therefore, we speculated that Rg1 may have similar effects on type H vessels. We used the Goto-Kakizaki (GK) rat model to perform immunofluorescence staining analysis on two markers of type H vessels, Endomucin (Emcn) and CD31, and the osteoblast-specific transcription factor Osterix, and found that Rg1 stimulates type H angiogenesis and bone formation. In vivo experiments also demonstrated that Rg1 promotes VEGF secretion, activates the Noggin/Notch pathway, increases the level of coupling between type H vessels and osteogenesis, and improves the bone structure of GK rats. All of these data reveal that Rg1 is a promising candidate drug for treating diabetic osteoporosis as a potentially bioactive molecule that promotes angiogenesis and osteointegration coupling.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied Diabetic osteoporosis (n=30). Ginsenoside Rg1 vs. Normal saline was evaluated on Bone mineral density and microstructural parameters (BV/TV, Tb.N, SMI, Tb.Sp) (p=<0.05). Ginsenoside Rg1 significantly improved bone mass and microstructural deterioration in diabetic rats by promoting type H angiogenesis and osteogenic coupling via the VEGF/Notch/Noggin pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: